Biotech Bulls: $MYNZ and $OMER Riding FDA Wave$OMER is rallying on FDA-related optimism, driven by advancements in treatment devices. $MYNZ, with its cutting-edge cancer diagnostic capabilities, is positioned to benefit from the same sector buzz. Both are capitalizing on key FDA developments, fueling long-term growth.